Background/Objective: Orphan drugs are medicinal products which treat life-threatening or chronically debilitating diseases which aff ect small patient populations. So far there is a substantial knowledge gap on actual expenditure on orphan drugs in Serbia. Therefore, the aim of this study was to provide insight into the expenditure trends of orphan drugs in Serbia. Material and methods: Annual reports on turnover and the consumption of pharmaceuticals in Serbia published by Medicines and Medical Devices Agency of Serbia (ALIMS) for the period 2006-2013 were used to extract data on expenditure on orphan drugs. Drugs were eligible for inclusion in the analysis if they had active European orphan designation and European marketing authorization during the period covered by the study (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013). Data were analysed across time series. Simple descriptive analysis and observation of chronological trends were applied. Results: Data for annual expenditure on 12 diff erent orphan drugs were available in the analysed reports. Orphan drug expenditure and share of orphan drug expenditure in total drug expenditure increased constantly from 2006 to 2010. Both began to slightly decrease over the next two years (2011)(2012), and then suddenly declined nearly threefold in 2013. Share of orphan drug expenditure didn't exceed 1% of total drug expenditure over a period of eight years. The highest share of expenditure on orphan drugs was attributed to imatinib (87.36%-97.13%), so abrupt decline in 2013 could be explained by its withdrawal from European Community Register of Orphan Medicinal Products in 2012. Conclusions: Expenditure on orphan drugs in Serbia from 2006 to 2013 was considerably low compared to total expenditure on drugs. In the last available year we noted substantial decline of orphan drug expenditure, mainly because of imatinib losing its orphan designation. A broader time horizon would be needed to investigate long term trends.
INTRODUCTION
Rare diseases also referred to as orphan diseases, are life-threatening or severely debilitating conditions with a low prevalence and a high level of complexity [1] . It is estimated that between 5,000 and 8,000 distinct rare diseases exist today, aff ecting between 6% and 8% of the population in the course of their lives [1] . In other words, although rare diseases are characterized by low prevalence for each of them, the total number of people aff ected by rare diseases in the European Union (EU) is between 27 and 36 million [1] . Because of their specifi city and the high total number of people aff ected, rare diseases call for a global approach based on special and combined efforts to prevent signifi cant morbidity or avoidable premature mortality, and to improve the quality of life and socioeconomic potential of aff ected persons [1] .
Governments of developed countries introduced the term "orphan drugs" in order to stimulate the pharmaceutical industry to develop and market medicinal products for the treatment of patients suff ering from rare conditions living in their own countries [2, 3] . Peculiar challenge in this area lies in the fact that societies have to provide economically sustainable model for pharmaceutical development where research and development costs will be compensated by return on investment guaranteed by the national governments or transnational funding instruments [4] . Surprisingly, unlike in recent economic history, emerging low and middle income nations are grabbing ever larger share of global pharmaceutical spending [5] .
Orphan drug legislation was fi rst introduced in the United States in 1983 in the form of Th e Orphan Drug Act [2, [6] [7] . Singapore introduced orphan drug legislation in 1991, Japan in 1993, Australia in 1998, the EU and Taiwan in 2000, and South Korea in 2003 [2, 6, [8] [9] . Authorities in Canada had announced the development of a framework for orphan drug legislation in 2012 [10] . Incentives provided to companies by orphan drug legislation include tax credits, fee reductions, assistance in formulating drug-development protocols (including scientifi c and technical support), accelerated marketing approval and market exclusivity up to 10 years if the drug is licensed [2, 8, 11] .
A medicinal product intended for use in the treatment of rare disease becomes an orphan drug when it is designated as an orphan medicinal product or orphan drug by the appropriate regulatory authority [2] . For instance, Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) is the regulatory authority in charge of granting orphan designations in the EU [2] . Still, granting a medicinal product orphan designation does not necessarily mean that it will also be granted marketing authorization [12] . Orphan designations are usually given based upon severity of the condition and unmet need (no therapeutic alternative or the new product provides signifi cant clinical benefi t), although criteria for designation vary somewhat among diff erent jurisdictions [13, 14] . In the EU an orphan medicinal product designation can be obtained if a drug is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition aff ecting not more than fi ve in 10 thousand persons in the EU, or for which without incentives it is unlikely that the marketing of the medicinal product in the EU would generate suffi cient return to justify the necessary investment [11] . Additional requirement is that no satisfactory method of diagnosis, prevention or treatment of the condition exists, or if it does exist, that the new product will be of signifi cant benefi t to those aff ected by that condition [11] . Orphan designation implies a 10-year period of market exclusivity, at the end of which the product is withdrawn from the Community Register of Orphan Medicinal Products [11] .Th e product could be removed earlier upon request of the marketing authorization holder [11] . Th e purpose of orphan drug legislation is to address the unmet health needs of rare disease patients, by providing innovative therapeutic options. Stimulating orphan drug research and development was a fundamental tool. Nevertheless, it is argued that current formulations of requirement for orphan designation can be misused to artifi cially create orphan diseases [15] . Th is can happen if drugs are intended for a specifi c type of patient/disease (so called "targeting") or when a disease is split into separate categories, each of which shows distinctive characteristics (so called "sub-setting") [15, 16] . Th is risk is especially evident in the oncology drugs fi eld [15, 16] . Th e majority of orphan drugs are indeed oncology-indicated [17] .
Th e market for orphan drugs is diswww.hophonline.org tinguishable because of specially designed regulation [18] . Orphan drugs are highly expensive due to market exclusivity, lack of alternative therapy and small market size [16, 18, 19] . Legislation in essence creates small virtual monopolies for each orphan drug [15, 20] . Investment in orphan drug development and marketing has become more favourable [21] . Although orphan drugs target much smaller number of patients than non-orphan drugs, the high cost of therapy and government incentives, smaller and shorter clinical trials and extended exclusivity have made them as equally viable [21] . When comparing prices of drugs intended for rare diseases, Picavet et al. found that orphan drug designation status is associated with higher prices [22] . Studies conducted in various countries reported that share of orphan drug expenditure had increased since introduction of orphan drug legislation [10, 18, [23] [24] [25] [26] [27] [28] . However, this share represented mainly low percentage (less than 8%) of overall drug expenditure [10, 18, [23] [24] [25] [26] [27] [28] . Picavet et al. observed that principal determinants in the market uptake of orphan drugs across 23 countries in Europe were the gross domestic product and the availability of a formal technology assessment organization [29] . Oncology orphan drugs are associated with highest percentage of expenditures on orphan drugs [10, 18, 24, 26, 28] . In Czech Republic oncology orphan drugs generated up to 72.6% of the overall orphan drugs expenditures in 2013 [26] . In Latvia oncology drugs represented 52.99% of the total orphan drug expenditures [18] . Th ese uneven shares point out to the diff erent pace and nature of pharmaceutical spending evolution among the old EU-15 compared to Eastern European nations [30] . A US study found that 74 (27.8%) orphan drugs with an orphan cancer indication had expenditures representing 26.7% (in 2007) and 34.8% (in 2013) of total orphan drug expenditures [28] .
Serbia still does not have its own orphan drug legislation [14, 31] . Th ere is no separate orphan drug marketing authorization process, although this procedure is simplifi ed if the drug has been authorized through the centralized procedure in the EU which is the case with the orphan drugs [14, 31, . Th ere is also a legal procedure for import of an unregistered drug as a donation or humanitarian aid [33] . Since Serbia is not a member of the EU, the country is not represented at EMA and COMP [31, 34] . However, the National Organisation for Rare Diseases of Serbia (NORBS) is a part of the European Organisation for Rare Diseases (EURORDIS) that has its delegates in the COMP [34, 35] .
Th e National Health Insurance Fund of Serbia is a national, public and non-profi t organization which is fi nanced by payment of health insurance contributions [36, 37] . In this way, citizens fi nance their healthcare by mediation of the Serbian Health Insurance Fund [36, 38] . One recently published study have shown that in 2011 only 4 orphan drugs were included in the reimbursement list, representing 6.5% of the market available orphan drugs in the EU [39] . Two years later, in 2013, only 9 of those medicinal products were registered in Serbia with only two (cladribine and imatinib) being actually reimbursed [40] . In order to be accessible to Serbian rare disease patients, an orphan drug has to be included in the Reimbursement list. A drug requires marketing authorization, as well as pharmacoeconomic evaluation to be included in Reimbursement List A, A1, B or C [41] . One exemption to this rule is a possibility to include an unregistered drug in the Reimbursement List D, if the drug is necessary in the treatment and diagnostics [42] . However, high price of orphan drugs is a considerable limiting factor for their inclusion in this list. If the National Health Insurance Fund cannot reimburse the expenditures related to the health care of patients aff ected by rare diseases, the Government of Serbia may allocate funding on an annual base [43] . Th e Government through the Ministry of Health allocated RSD 130 million (around EUR 1.2 million) in 2013, with RSD 280 million (around EUR 2.6 million) planned for this purpose in 2014 [31] . Th is amount was intended for treatments for only a handful of paediatric patients with metabolic diseases requiring enzyme replacement therapies [31] . In 2015 the Ministry of Health allocated RSD 335.2 million (around EUR 2.8 million) [44] and in 2016 it almost doubled the amount RSD 600 million (around EUR4.9 million) [45] intended for health care of patients with rare diseases. However, all of this is still not enough to cover the healthcare expenditure of estimated 500,000 of patients with various rare diseases in Serbia [39] . A proposal for a national Strategy on Rare Diseases was developed in 2013 envisioning a number of actions, including improving diagnostics and availability of orphan drugs [31] . Even so, the Strategy has not been offi cially adopted yet and there is still no national registry for rare diseases, although there are national registries for individual rare diseases (cystic fi brosis, haemophilia and rare coagulopathies) [31] .
Total public expenditure on pharmaceuticals in Serbia constantly increased from 2004 to 2012 [46, 47] . At the same time not all segments of pharmaceutical market had shown the same trend [46] [47] [48] . Market growth was primarily driven by cardiovascular medicines, targeted oncology agents and a variety of advanced biologicals [46] . So far there is a substantial knowledge gap on actual expenditure on orphan drugs in Serbia. Th erefore, the aim of this study was to provide insight into the expenditure trends of orphan drugs in Serbia.
MATERIAL AND METHODS
Annual reports on turnover and consumption of pharmaceuticals in Serbia published by ALIMS were used as main data source. Th ese reports are publicly available on ALIMS website for the period 2006-2013 [49] [50] [51] [52] [53] [54] [55] [56] . Th ey are based on information about amount of imported pharmaceuticals and their market placement provided by manufacturers and their legal representatives in Serbia. Data in these reports are ordered by Anatomical Th erapeutic Chemical (ATC) classifi cation codes. Each ATC code group and each single product are assigned fi nancial value of its sales in national currency, Serbian Dinar (RSD).
Currently, there is no offi cial list of orphan designated medicinal products in Serbia. Th erefore, this analysis used information on market authorized orphan drugs in the EU from Orphanet, expert-authored and peerreviewed database of rare diseases [57] . Drugs were eligible for inclusion in the analysis if they had active European orphan designation and European marketing authorization during the period covered by the study (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) .
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We included drugs in the analysis until the end of the year in which they were formally considered orphan medicinal products in Europe. Information on ATC code and pharmaceutical form of each authorized drug was obtained from the Summary of product characteristics from the EMA website [58] . Th e same website was used to check exact dates of inclusion and/ or withdrawal of the drug from the European Community Register of designated Orphan Medicinal Products. Th ese data were then cross-referenced with data on expenditure in the annual reports of ALIMS.Annual expenditure for each orphan drug was extracted considering ATC, INN and marketed pharmaceutical form. Information on total annual expenditure on pharmaceuticals in Serbia was also extracted. Average middle exchange rate for Euro (EUR) given by the National Bank of Serbia for each observed year was used to convert expenditures originally reported in the national currency (RSD) [59] . Average annual middle exchange rates for EUR 1 were 
RESULTS
Data for annual expenditure on 12 diff erent orphan drugs were available in ALIMS reports during the period covered by the study (Table  1a and Table 1b ). Most of them (8 drugs, i.e. 66.67%) belonged to ATC category L (Antineoplastic and immunomodulating agents), two (16.67%) to category A (Alimentary tract and metabolism), one (8.33%) to category B (Blood and the blood forming organs) and one (8.33%) to category C (Cardiovascular system).
Th e lowest orphan drug expenditure was observed in 2006 (around RSD 127 million, i.e. EUR 1.5 million), whereas the highest was observed in 2010 (around RSD 754 million, i.e. EUR 7.3 million) (Table 1a and Table  1b Th e highest annual expenditure increment of orphan drugs was attributed to imatinib ( Orphan Medicinal Products. Th erefore,the observed abrupt decline in 2013 could be explained by this event. If we exclude imatinib from analysed data we can notice a totally different trend. Orphan drug expenditure without imatinib increased more than 7-fold with occasional variations from around RSD 6 million (EUR 71 thousand) in 2006 to around RSD 93 million (EUR 824 thousand) in 2012 (Table 1a  and Table 1b ). Increase was most prominent in 2013 with orphan drug expenditure almost 2.5-fold greater than the one in previous year (around RSD 235 million, i.e. EUR 2.1 million) (Red line on Figure 1 ). Share of orphan drug expenditure in total drug expenditure also showed a similar trend(Red line on Figure 2 1% of total drug expenditure over a period of eight years. Th is percentage is similar to that reported in 2004 in an early European study (0.7-1% per country) [60] and in one recently published Latvian study for 2010-2014 (0.70-1.04%) [18] . However, when comparing these results, it should be kept in mind that methods and data sources vary signifi cantly (sales data, national health care funds etc.). Access to orphan drugs depends on individual country's pricing and reimbursement policies. Subsequent studies in Europe reported slightly higher share of orphan drug expenditure in total drug expenditure. Average budget impact of orphan drugs represented 1.7% of the total expenditure on drugs in 2007 across the fi ve countries (the United Kingdom, Germany, Italy, Spain and France) [61] . Th e budget impact of orphan drugs represented 2.5% of total drug expenditure in Sweden and 3.1% in France in 2012 [62] . Th e share of orphan drugs in total pharmaceutical market in 2013 reached 3.6% in Czech Republic [26] and 3.2% in Poland [27] . Th e Netherlands reported highest share of 4.2% in 2012 [23] . Countries located in North America reported even higher shares. Share of orphan drug expenditure in total pharmaceutical drug expenditure reached 5.6% in Canada [10] and 7.6% in the United States in 2013 [28] . Such high share reported in the United States is certainly not surprising, considering the fact that it was the fi rst country which introduced orphan drug legislation. Share of orphan drug expenditure in total drug expenditure in Serbia increased constantly from 2006 to 2010. It began to slightly decrease over the next two years (2011-2012), and then it suddenly declined nearly threefold in 2013 due to withdrawal of imatinib from the European Community Register of Orphan Medicinal Products. Decline was striking, from 0.87% in 2012 to only 0.26% in 2013. Similar occurrence was noted in Latvia, only the decline was not so abrupt [18] . In Latvia share of total pharmaceutical market attributed to orphan drugs decreased from 1.04% in 2012 to 0.70% in 2013 [18] . Th is diff erence could be explained by the fact that imatinib constituted from 87.36% to 97.13% of all orphan drug expenditures in Serbia, whereas in Latvia it was about 34% [18] . When change in share of orphan drug expenditure was analysed without imatinib, more-less constant increase was observed from 2006 to 2013 in Serbia. Similar trend was reported for Latvia [18] . ALIMS has not yet made publicly available the annual report on turnover and consumption of drugs for 2014 on its website [63] , so we do not know if orphan drug expenditure increased in the following year. In Latvia it increased to 0.84% in 2014 [18] . Orofi no et al. described similar budget impact of imatinib in the study that only considered orphan drug expenditure in 2007 across the fi ve countries (the UnitedKingdom, Germany, Italy, Spain and France) [61] . Sales of imatinib in all fi ve countries accounted EUR 679 million, which was 41.2% of the total expenditure on the 38 orphan drugs [61] . Th ey stipulated that if they excluded the expenditure corresponding to the three drugs that each had sales that exceeded EUR 150 million (sunitinib, bosentan and imatinib), the impact of the remaining 35 orphan drugs on the overall drug expenditure in the fi ve countries would be more than halved, from 1.7% to 0.65% [61] . Some argue that the distribution of orphan drug sales is skewed, and that the success of some outlier orphan drugs, such as imatinib, has contributed to an impression that orphan drugs consistently achieve high sales [62] . Some other European countries reported more-less constant growth of orphan drug budget impact [62] . In Sweden it grew at a steady rate from introduction of orphan drug legislation reaching 0.7% of total drug sales in 2006 [62] . Th e budget impact growth rate accelerated between 2006 and 2009, and then slowed down reaching 2.5% of total pharmaceutical market value in 2012 [62] . In Czech Republic share of orphan drugs in total pharmaceutical sales grew steadily from 2.5% in 2008, reaching 3.4% in 2011 and plateaued at 3.6% in 2013 [26] .
Lower share of expenditures on orphan drugs in Serbia might be explained by the discrepancies in the marketing authorization, pricing and reimbursement of orphan drugs compared to the EU and other countries [34] . Th ese are indeed very common challenges to orphan drug access in Eastern Europe [64] . Lack of epidemiological registries and low public awareness on rare diseases are also aggravating this problem [64] . Since Serbia is not an EU Member State there is no centralised marketing authorization procedure and the registration procedure can take up to one year, which leads to delay in access to orphan drugs [31, 34] . Considering the fact that there is usually no diff erence in prices of orphan drugs between developed and less developed countries, it is harder for patients in less developed countries to aff ord such treatments [65] . Drugs for some rare disease are frequently dowww.hophonline.org nated by charity for the most severe cases until the state accepts participation in the fi nancing of treatment [65] . However, majority of patients aff ected by rare diseases in Serbia stil cannot get reimbursement for their treatment from the Republic Health Insurance Fund [31, 65] .
Only a minority of expenditures on orphan drugs was associated with non-oncological indications: Fabry's disease (agalsidase beta (Fabrazyme®) Current studies suggest that orphan drug expenditure will likely remain a small proportion of total pharmaceutical expenditure [10, 62, 67] . Th e impact of orphan drugs on the total European pharmaceutical market was predicted to increase from 3.3% in 2010 to 4.6% in 2016 [67] . Share of orphan drug expenditure in the total pharmaceutical market was forecasted to grow to 4.1% in Sweden and 4.9% in France by 2020 [62] . Future trend analysis in Canada suggested that orphan drug expenditure in 2014-2018 will remain stable below 6% of total drug expenditure [10] . It remains to be seen how orphan drug market will continue to evolve in Serbia.
Study limitations
In our research we focused only on drugs that were orphan designated during the period covered by our study. Not all drug therapies intended for rare diseases are orphan designated. Furthermore, current orphan drug legislation provides a possibility for a drug to be orphan designated even if it is intended to treat a subset of the patient population with a common disease. So we did not capture expenditure on all drugs intended for rare disease treatment.
ALIMS annual reports are based on information about amount of imported and priced pharmaceuticals and their market placement provided by manufacturers and their legal representatives. So, these reports give only an approximate amount of sales generated without considering specifi c terms of sale.
Moreover, real drug use may diff er from that refl ected in the sales data. Orphan drugs are provided to some patients through donations, and therefore, the sales data do not capture this. Th e time period in our study was limited to a period of eight years. In the last available year we noted substantial decline of orphan drug expenditure, mainly because of imatinib losing its orphan designation. A broader time horizon would be needed to investigate long term trends.
CONCLUSION
Total spending on orphan drugs represented a small share of overall expenditure on drugs during the observed period (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Share of orphan drug expenditure didn't exceed 1% of total drug expenditure over a period of eight years. Orphan drug expenditure and share of orphan drug expenditure in total drug expenditure increased constantly from 2006 to 2010. It began to slightly decrease over the next two years (2011-2012), and then it suddenly declined nearly threefold in 2013. More than 87% of expenditure on orphan drugs was attributed to imatinib, so abrupt decline in 2013 could be explained by its withdrawal from European Community Register of Orphan Medicinal Products in 2012. When imatinib was excluded from analysis, both orphan drug expenditure and share of orphan drug expenditure in total drug expenditure increased constantly with slight variations. A broader time horizon would be needed to investigate long term trends.
